Table 2 Ongoing clinical trials to target MDSCs in cancer patients
From: Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Target | Agent | Tumor types and combinational therapies | Phase | Sample size | Clinical trial number |
|---|---|---|---|---|---|
CXCR2 inhibitor | AZD5069 | Metastatic Castration Resistant Prostate Cancer + Enzalutamide | I/II | 86 | NCT03177187 |
SX-682 | Pancreatic Cancer + Nivolumab | I | 20 | NCT04477343 | |
Melanoma + Pembrolizumab | I | 77 | NCT03161431 | ||
CCR5 inhibitor | Vicriviroc | Advanced/Metastatic Microsatellite Stable Colorectal Cancer + Pembrolizumab | II | 42 | NCT03631407 |
Maraviroc | Advanced Metastatic Colorectal and Pancreatic Cancer + Nivolumab + Ipilimumab | I | 50 | NCT04721301 | |
CCR5 antibody | Leronlimab | Locally Advanced or Metastatic Solid Tumors | II | 30 | NCT04504942 |
STAT3 inhibitor | OPB-31121 | Advanced Cancers | I | 24 | NCT00955812 |
AZD9150 | Advanced Solid Tumors + Durvalumab | I | 76 | NCT03421353 | |
WP1066 | Recurrent Malignant Glioma and Brain Metastasis from Melanoma | I | 33 | NCT01904123 | |
TTI-101 | Advanced Cancers | I | 60 | NCT03195699 | |
SC-43 | Advanced NSCLC and Advanced Biliary Tract Cancer + Cisplatin | I/II | 100 | NCT04733521 | |
OPB-51602 | Advanced Cancer | I | 45 | NCT01423903 | |
JAK/STAT3 inhibitor | Ruxolitinib | Head and Neck Squamous Cell Carcinoma | II | 45 | NCT03153982 |
PDE5 inhibitor | Tadalafil | Head and Neck Squamous Cell Carcinoma | II | 40 | NCT01697800 |
Sildenafil | Solid Tumor + Regorafenib | I | 32 | NCT02466802 | |
COX2 inhibitor | Celecoxib | Lung Cancer + Radiation Therapy | I/II | 21 | NCT00046839 |
Colon Carcinoma + Nivolumab/Ipilimumab | II | 60 | NCT03026140 | ||
Breast Cancer | III | 2639 | NCT02429427 | ||
Cervix Neoplasms | I/II | 31 | NCT00152828 | ||
Endometrium Cancer | II | 48 | NCT03896113 | ||
HDAC inhibitor | Entinostat | Metastatic Colorectal Cancer + Azacitidine | II | 47 | NCT01105377 |
Vorinostat | Locally Advanced NSCLC + Chemotherapy and Radiation Therapy | I | 18 | NCT01059552 | |
Malignant Solid Tumor + Hydroxychloroquine | I | 72 | NCT01023737 | ||
Quisinostat | NSCLC/Epithelial Ovarian Cancer + Chemotherapy | I | 51 | NCT02728492 | |
SB939 | Prostate Cancer | II | 32 | NCT01075308 | |
Panobinostat | Melanoma + Ipilimumab | I | 17 | NCT02032810 | |
Chidamide | Cervical Cancer + Toripalimab | I/II | 40 | NCT04651127 | |
CHR-3996 | Solid Tumor | I | 40 | NCT00697879 | |
Vitamins | ATRA | Breast Cancer + Anastrozole | II | 112 | NCT04113863 |
Pancreatic Cancer + Chemotherapy | II | 170 | NCT04241276 | ||
Prostate Cancer + 5-Azacitidine + Lupron | II | 20 | NCT03572387 | ||
Melanoma + Pembrolizumab | I/II | 26 | NCT03200847 | ||
Casein kinase inhibitor | Silmitasertib (CX 4945) | Advanced Basal Cell Carcinoma | I | 26 | NCT03897036 |
Cholangiocarcinoma + Chemotherapy | I/II | 127 | NCT02128282 | ||
Chemotherapy | Low-Dose Capecitabine + Bevacizumab | Glioblastoma | I | 12 | NCT02669173 |
LXR Agonist | RGX-104 | Malignant Neoplasms + Immunotherapy/Chemotherapy | I | 135 | NCT02922764 |
Tyrosine kinase inhibitor | Pazopanib | Solid Tumors | II | 57 | NCT01956669 |
Solid Tumors + Topotecan | I/II | 66 | NCT02303028 | ||
Sarcoma + Durvalumab | II | 37 | NCT03798106 | ||
Ibrutinib | Malignant Solid Tumors + Nivolumab | I | 15 | NCT03525925 | |
Lung Cancer | I/II | 13 | NCT02321540 | ||
Gastroesophageal Cancer | II | 17 | NCT02884453 |